Back to top
more

Aurora Cannabis (ACB)

(Delayed Data from NSDQ)

$4.48 USD

4.48
1,765,197

+0.05 (1.13%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $4.48 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 30% (173 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Are Medical Stocks Lagging Aurora Cannabis (ACB) This Year?

by Zacks Equity Research

Here is how Aurora Cannabis Inc. (ACB) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.

Zacks Equity Research

Aurora Cannabis Inc. (ACB) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Aurora Cannabis Inc. (ACB) delivered earnings and revenue surprises of 11.11% and 2.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Aurora Cannabis (ACB) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Continued strength in Aurora Cannabis' (ACB) domestic adult recreational segment is expected to have driven Q1 sales.

Zacks Equity Research

Eagle Pharmaceuticals (EGRX) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 33.33% and 11.01%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

MacroGenics (MGNX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

MacroGenics (MGNX) delivered earnings and revenue surprises of 18.37% and 83.52%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ResMed (RMD) Q1 Earnings Match Estimates

by Zacks Equity Research

ResMed (RMD) delivered earnings and revenue surprises of 0% and 0.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Aurora Cannabis Inc. (ACB) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aurora Cannabis Inc. (ACB) delivered earnings and revenue surprises of 33.33% and 0.30%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

High Tide Inc. (HITI) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

High Tide Inc. (HITI) delivered earnings and revenue surprises of 57.14% and 8.29%, respectively, for the quarter ended July 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Evolus, Inc. (EOLS) delivered earnings and revenue surprises of 34.15% and 12.03%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Eagle Pharmaceuticals (EGRX) Q1 Earnings Top Estimates

by Zacks Equity Research

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 3.32% and 5.32%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Aurora Cannabis Inc. (ACB) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aurora Cannabis Inc. (ACB) delivered earnings and revenue surprises of -147.06% and 4.79%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Aurora Cannabis Inc. (ACB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Aurora Cannabis Inc. (ACB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Aurora Cannabis Inc. (ACB) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Aurora Cannabis Inc. (ACB) closed at $5.50, marking a +0.92% move from the previous day.

Zacks Equity Research

Implied Volatility Surging for Aurora Cannabis (ACB) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Aurora Cannabis (ACB) stock based on the movements in the options market lately.

Zacks Equity Research

Aurora Cannabis Inc. (ACB) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Aurora Cannabis Inc. (ACB) delivered earnings and revenue surprises of 50.00% and -0.21%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Aurora Cannabis (ACB) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Continued strength in Aurora Cannabis' (ACB) domestic-adult-recreational segment is expected to have driven Q1 sales.

Zacks Equity Research

Aurora Cannabis Inc. (ACB) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Aurora Cannabis Inc. (ACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Aurora Cannabis Inc. (ACB) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Aurora Cannabis Inc. (ACB) delivered earnings and revenue surprises of 0.00% and -2.78%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Aurora Cannabis Inc. (ACB) Q4 Earnings Expected to Decline

by Zacks Equity Research

Aurora Cannabis Inc. (ACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Madeleine Johnson headshot

Why Cannabis Giant Tilray (TLRY) Skyrocketed Today

by Madeleine Johnson

Shares of Tilray (TLRY) closed sharply higher in Wednesday's trading session, gaining 25.8% after reporting mixed fourth-quarter earnings results.

Zacks Equity Research

Aurora Cannabis Inc. (ACB) Stock Jumps 7.7%: Will It Continue to Soar?

by Zacks Equity Research

Aurora Cannabis Inc. (ACB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Aditi Saraogi headshot

Do Options Traders Know Something About Aurora Cannabis (ACB) Stock We Don't?

by Aditi Saraogi

Investors need to pay close attention to Aurora Cannabis (ACB) stock based on the movements in the options market lately.

Zacks Equity Research

Company News for May 17, 2021

by Zacks Equity Research

Companies In The News Are: ACB, NEWR, BLFS, GLOB

Zacks Equity Research

Aurora Cannabis Inc. (ACB) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Aurora Cannabis Inc. (ACB) delivered earnings and revenue surprises of -41.18% and -21.05%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Aurora Cannabis (ACB) to Post Q3 Earnings: What's in Store?

by Zacks Equity Research

Aurora Cannabis' (ACB) sturdy consumer cannabis sales are likely to have benefited its performance in the fiscal third quarter.